Identification of the Key MicroRNAs and the miRNA-mRNA Regulatory Pathways in Prostate Cancer by Bioinformatics Methods

Table 4

Results of the significant DEMs expression validation and the relationship with PCa clinical stages in TCGA data.

MiRNA ID	Up-regulated in	P-value (t-test)	Clinical stages	P-value (chi-square)
hsa-miR-133a-3p	normal	8.93E-03	pathologic T/ N status	9.50e-09/ 1.32e-04
hsa-miR-133b	normal	9.53E-07	pathologic T/ N status	7.96e-07/ 8.83e-05
hsa-miR-143-3p	normal	1.10E-13	clinical T/ M status	5.04e-03/3.70e-03
hsa-miR-145-3p	normal	1.65E-07	pathologic T/ N status	7.86e-07/ 1.49e-04
hsa-miR-148a-3p	tumor	7.67E-13	-	-
hsa-miR-148a-5p	tumor	4.66E-10	pathologic T status	2.10e-03
hsa-miR-153-3p	tumor	4.12E-20	pathologic T status	4.30e-02
hsa-miR-182-5p	tumor	7.57E-16	clinical T/ M status	4.23e-03/ 3.06e-02
hsa-miR-183-5p	tumor	1.56E-15	pathologic T status/; Clinical M Status	7.85e-03/ 1.25e-03
hsa-miR-187-3p	normal	1.52E-10	-	-
hsa-miR-204-5p	normal	2.62E-06	pathologic T/ N status	2.44e-03/ 1.77e-02
hsa-miR-205-5p	normal	1.39E-02	pathologic T status	1.17e-02
hsa-miR-221-3p	normal	6.18E-10	pathologic T/ N status	4.10e-07/ 3.70e-04
hsa-miR-221-5p	normal	1.44E-05	pathologic T/ N status	5.69e-03/ 5.19e-03
hsa-miR-222-3p	normal	5.76E-07	pathologic T/ N status	4.71e-09/ 2.77e-04
hsa-miR-222-5p	normal	1.17E-04	pathologic T status/; Clinical M Status	1.37e-03/ 4.81e-02
hsa-miR-224-5p	normal	2.31E-02	pathologic T status	5.62e-04
hsa-miR-23b-3p	normal	8.14E-03	pathologic T/ N status	9.60e-03/ 3.24e-02
hsa-miR-31-3p	normal	3.97E-02	-	-
hsa-miR-32-3p	tumor	2.96E-03	pathologic T/ N status	3.29e-03/ 3.81e-02
hsa-miR-363-3p	tumor	1.18E-08	pathologic N status	2.92e-02
hsa-miR-375	tumor	8.87E-13	-	-
hsa-miR-550a-5p	tumor	1.08E-04	-	-
hsa-miR-7-5p	tumor	1.70E-03	pathologic T/ N status	4.28e-02/ 2.03e-03
hsa-miR-95-3p	tumor	8.29E-06	pathologic T status	7.17e-03
hsa-miR-96-5p	tumor	1.65E-15	pathologic N status/; Clinical M Status	4.72e-02/ 5.81e-03